National Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
|
|
- Ashley Rose
- 5 years ago
- Views:
Transcription
1 Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The Research Programme is part of the National Institute for Health Research
2 Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer Target group Non-small cell lung cancer (NSCLC) - locally advanced or metastatic (stage IIIB and IV) disease, in combination with bevacizumab (Avastin): second-line therapy after failure of standard first-line therapy; maintenance therapy after standard first-line therapy. Technology description Erlotinib (Tarceva, CP , OSI-774, R-1415) is an orally-active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is used as a second-line monotherapy (150mg daily) for patients with locally advanced or metastatic NSCLC. Bevacizumab (Avastin) is an intravenous humanised anti-vascular endothelial growth factor (VEGF) monoclonal antibody, which inhibits VEGF-induced signalling and partially inhibits VEGF-driven angiogenesis. It is used in combination with platinumbased agents as first-line therapy, and administered as 7.5mg/kg or 15mg/kg of body weight once every three weeks by intravenous (iv) infusion. Innovation and/or advantages Combining the anti-egfr agent erlotinib with the anti-angiogenic agent bevacizumab may provide an alternative to conventional cytotoxic chemotherapy, offering improved efficacy and reduced toxicity. Erlotinib is orally bioavailable, and better tolerated than the standard second-line chemotherapy agent docetaxel. Developer Roche Products Ltd. Place of use Home care erlotinib Secondary care - non-specialist hospital capable of chemotherapy - bevacizumab General public e.g. over the counter Community or residential care e.g. district nurses, physio Tertiary care bevacizumab (iv infusion every 21 days) Primary care e.g. used by GPs or practice nurses Emergency care e.g. paramedic services, trauma care Availability, launch or marketing dates, and licensing plans: In phase III clinical trials. NHS or Government priority area: This topic is relevant to the NHS Cancer Plan. Relevant guidance NICE clinical guideline Lung Cancer: the diagnosis and treatment of lung cancer (expected review date February 2009) 1. NICE technology appraisals Pemetrexed for the treatment of non-small cell lung cancer
3 Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (now replaced by NICE Clinical Guideline on Lung Cancer, 2005) 3. Bevacizumab for non-small cell lung cancer. Expected January Erlotinib for advanced non-small cell lung cancer. Expected April Scottish Intercollegiate Guidelines Network (SIGN): Management of patients with lung cancer European Society for Medical Oncology (ESMO): Minimum clinical recommendations for the diagnosis, treatment and follow-up of non-small cell lung cancer US National Comprehensive Cancer Network (NCCN): clinical practice guideline on non-small cell lung cancer Clinical need and burden of disease Lung cancer is the most common cause of death in the UK. In England and Wales there were 32,715 new cases diagnosed in 2004, with 28,632 deaths registered in 2005 (around 54 deaths per 100,000 of population) 9. In England and Wales lung cancer has a one-year survival rate of 25% and a five-year survival rate of 7% 10. NSCLC accounts for approximately 80% of all lung cancers. Approximately 75% of newly diagnosed patients already have advanced (stage III or IV) disease 11 (around 24,536 patients in England and Wales), with a five-year survival rate of less than 1% 12. NICE estimates that around 25% of patients with advanced NSCLC receive first-line chemotherapy 13. Around 30-40% of these patients may subsequently become candidates for second-line therapy (approximately 1,840-2,454 patients) 14. Existing comparators and treatments Treatment options for stage IIIB or IV NSCLC include radiation therapy, chemotherapy with radiation therapy, and chemotherapy alone. Chemotherapy may be recommended for patients with non-resectable stage III or IV disease provided they have a good performance status. Current NICE guidance recommends that first-line chemotherapy should include a combination of a platinum drug (cisplatin or carboplatin) and a single third generation drug, such as docetaxel, gemcitabine, pacitaxel or vinorelbine. Second-line therapy options include: docetaxel (Taxotere) monotherapy. erlotinib (Tarceva) monotherapy licensed and NICE guidance expected April pemetrexed (Alimta) licensed but not currently recommended by NICE. bevacizumab (Avastin) licensed for first-line combination therapy; NICE guidance expected January gefitinib (Iressa) experimental use in clinical trials, not in current practice (unlicensed). Efficacy and safety Trial name or code BeTa/NCT ; second-line. Phase III NCT ; secondline. Phase II ATLAS/NCT ; maintenance. Phase III Sponsor Genentech Genentech Genentech Status In progress Published 15 In progress Location Multicentre Multicentre USA 3
4 Design Randomised, placebo- controlled, double-blind. Randomised. Randomised, placebo- controlled, double-blind. Participants N=650; failed first-line N=120; failed platinum- N=1,150; advanced chemotherapy or chemoradiotherapy. Randomised to erlotinib + bevacizumab, or erlotinib alone. or pemetrexed) based regimen. Randomised to bevacizumab + erlotinib (B+E); bevacizumab + chemotherapy (docetaxel (B+chemo); NSCLC (stage IIIB/IV) or non-progressive disease, after first-line chemotherapy with bevacizumab. Randomised to erlotinib + bevacizumab or bevacizumab alone. or chemotherapy alone (chemo). Primary Overall survival Progression-free survival Progression-free survival outcome Secondary Progression-free survival Overall survival (OS) Adverse events, outcomes (PFS), objective response, discontinuations, overall duration of response. survival. Results Expected Q No significant difference Expected Q 2009 in progression or death relative to chemo alone. Median OS: 13.7, 12.6 and 8.6 months for B+E, B+chemo, and chemo respectively; one-year survival was 57.4%, 53.8%, and 33.1% respectively. Adverse - Grade 5 haemorrhage with - effects bevacizumab 5.1%; consistent with previous trials. Estimated cost and cost impact Erlotinib costs around 6,800 a for a course lasting 125 days (treatment duration taken from second-line studies). The intended duration of treatment for maintenance use is not known. Potential or intended impact speculative Patients Reduced morbidity Reduced mortality or increased survival Improved quality of life for patients and/or carers - fewer adverse events, e.g. neutropenia Quicker, earlier or more accurate None identified diagnosis or identification of disease Services Increased use capacity issues Service reorganisation required Staff or training required in relation to administration of intravenous therapies. Decreased use lower toxicity compared to standard treatment None identified a British National Formulary edition 53, March
5 Costs Increased unit cost compared to alternative New costs: Increased costs: more patients coming for treatment Savings: Increased costs: capital investment needed References 1 National Institute for Health and Clinical Excellence. Lung Cancer: The diagnosis and treatment of lung cancer. Clinical Guideline 24, February National Institute for Health and Clinical Excellence. Pemetrexed for the treatment of non-small cell lung cancer. Technology Appraisal 124, August National Institute for Health and Clinical Excellence. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer. Technology Appraisal 26, 2001 (now replaced by NICE Clinical Guideline 24). 4 National Institute for Health and Clinical Excellence. Bevacizumab for the treatment of non-small cell lung cancer.. Technology Appraisal in development - publication expected January National Institute for Health and Clinical Excellence. Erlotinib for the treatment of advanced non-small cell lung cancer.. Technology Appraisal in development - publication expected April Scottish Intercollegiate Guidelines Network (SIGN): Management of patients with lung cancer, Guideline 80, February ESMO: Minimum clinical recommendations for the diagnosis, treatment and follow-up of non-small cell lung cancer (NSCLC). Annals of Oncol 2005; 16 (1): National Comprehensive Cancer Network (NCCN): clinical practice guideline on non-small cell lung cancer, September Cancer Research UK, Cancer Stats Lung cancer and smoking UK, July Coleman M, Rachet B, Woods L et al. Trends in socio-economic inequalities in cancer survival in England and Wales up to 2001, British Journal of Cancer 2004; 90(7): Liverpool Reviews and Implementation Group, ERG Report Pemetrexed for the treatment of relapsed nonsmall cell lung cancer, September 2006, London: National Institute for Clinical Excellence 12 National Collaborating Centre for Acute Care, The diagnosis and treatment of lung cancer: methods, evidence and guidance; February 2005, London: National Collaborating Centre for Acute Care. 13 National Institute for Clinical Excellence (NICE) technology appraisal in development: Bevacizumab for the treatment of non small cell lung cancer final scoping document April 2007, accessed online 20 Nov 2007 at 14 Hu C, Davies AM, Lara PN et al. Second-line treatment for advanced-stage non-small cell lung cancer: current and future options. Clinical Lung Cancer 2006; 7(4): S Herbst RS, O Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007; 25 (30): The National Institute for Health Research Research Programme is funded by the Department of Health. The views expressed in this publication are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health The, D epartment of Public Health and Epidemiology University of B irmingham, Edgbaston, Birmingham, B15 2TT, England Tel: +44 (0) Fax +44 (0)
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationHorizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. GV1001 for advanced and/or metastatic pancreatic cancer. April 2008
GV1001 for advanced and/or metastatic pancreatic cancer April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNational Horizon Scanning Centre. Ampligen for chronic fatigue syndrome. December 2007
Ampligen for chronic fatigue syndrome December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationHorizon Scanning Technology Summary. Methylnaltrexone for opioid induced constipation in advanced illness and palliative care
Horizon Scanning Technology Summary National Horizon Scanning Centre Methylnaltrexone for opioid induced constipation in advanced illness and palliative care April 2007 This technology summary is based
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationHorizon Scanning Technology Summary. Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Cyanocobalamin nasal spray (Nascobal) for vitamin B12 deficiency April 2007 This technology summary is based on information available
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationBevacizumab for the treatment of recurrent advanced ovarian cancer
Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationHorizon Scanning Technology Briefing. Alvimopan (Entrareg ) for opioid-induced bowel disfunction. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Alvimopan (Entrareg ) for opioid-induced bowel disfunction August 2006 This technology briefing is based on information available at
More informationNational Horizon Scanning Centre. Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids.
Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids May 2008 This technology summary is based on information available at the time of research and a limited
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 June 2012 TARCEVA 25 mg, film-coated tablet B/30 (CIP code: 369 232 3) TARCEVA 100 mg, film-coated tablet B/30 (CIP
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationEli Lilly and Company Ltd
www.lilly.co.uk Eli Lilly and Company Limited Lilly House Priestley Road Basingstoke Hampshire RG24 9NL Medical and Product Information: +44 (0) 1256 315999 28 February 2007 Mr Christopher Feinmann Technology
More informationHorizon Scanning Technology Briefing National Helical Tomotherapy Horizon Hi-ART System for Scanning external cancer Centre radiotherapy August 2006
Horizon Scanning Technology Briefing National Horizon Scanning Centre Helical Tomotherapy Hi-ART System for external cancer radiotherapy August 2006 This technology briefing is based on information available
More informationNational Horizon Scanning Centre. Methylnaltrexone (MOA-728) for postoperative ileus. April 2008
(MOA-728) for postoperative ileus April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationTechnology appraisal guidance Published: 28 July 2010 nice.org.uk/guidance/ta192
Gefitinib for the first-line treatment of locally advanced or metastatic non-small- cell lung cancer Technology appraisal guidance Published: 28 July 2010 nice.org.uk/guidance/ta192 NICE 2018. All rights
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationTechnology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta284
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta284 NICE 2017.
More informationTechnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta402
Pemetrexed ed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed ed and cisplatin Technology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta402 NICE
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationMedia Release. Basel, 7 May 2018
Media Release Basel, 7 May 2018 FDA grants priority review to Roche s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche
More informationRilonacept for cryopyrin associated periodic syndromes
Rilonacept for cryopyrin associated periodic syndromes August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationBevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationRe-Submission. Scottish Medicines Consortium. erlotinib, 100 and 150mg film-coated tablets (Tarceva ) No. 220/05 Roche. 5 May 2006
Scottish Medicines Consortium Re-Submission erlotinib, 100 and 150mg film-coated tablets (Tarceva ) No. 220/05 Roche 5 May 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationSystemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationData will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)
Investor Update Basel, 20 November 2017 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening
More informationPemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
DOI: 10.3310/hta14suppl2/05 Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer J Greenhalgh,* C McLeod, A Bagust, A Boland, N Fleeman, Y Dundar, J Oyee,
More informationTechnology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer Technology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
More informationFinal PROTOCOL. This report was commissioned by the NIHR HTA Programme as project number 12/49/01. Completed 28 th March 2013 DOES NOT CONTAIN CIC/AIC
Final PROTOCOL Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175) This report was commissioned
More informationTechnology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation- positive non-small-cell lung cancer Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416 NICE
More informationHorizon Scanning Technology Summary. Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease
Horizon Scanning Technology Summary National Horizon Scanning Centre Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease April 2007 This technology summary is based
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More informationIs Bevacizumab (Avastin) Safe and Effective as Adjuvant Chemotherapy for Adult Patients With Stage IIIb or IV Non-Small Cell Lung Carcinoma (NSCLC)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Bevacizumab (Avastin) Safe and Effective
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationLead team presentation:
Lead team presentation: Nivolumab for previously treated locally advanced or metastatic nonsquamous non-small-cell lung cancer 1 st Appraisal Committee meeting Background & Clinical Effectiveness Iain
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More information